Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 18, 2008. The report details a specific corporate action regarding a share buyback executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 250,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,201.77 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.11% of total voting rights).
- Shares in Issue: 5,207,175,385 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 250,000 shares purchased on November 18, 2008. Consequently, the Company's Treasury shareholding now represents 9.11% of total voting rights. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,207,175,385) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its percentage of voting rights (9.11%).
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.